Takeda Pharmaceutical (TAK) Non-Current Assets (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Non-Current Assets of $78.5 billion for Q2 2026, down 1.15% year-over-year from $79.4 billion in Q2 2025, and down 0.88% quarter-over-quarter from $79.2 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Non-Current Assets (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Non-Current Assets history runs 10 years deep, the most recent figure standing at $78.5 billion for Q2 2026.
- In Q2 2026, Non-Current Assets fell 1.15% year-over-year to $78.5 billion; the TTM figure through Jun 2026 stood at $78.5 billion (down 1.15% YoY), while the FY2026 annual figure was $82.5 billion, up 7.18% from the prior year.
- Non-Current Assets for Q2 2026 stood at $78.5 billion, down from $79.2 billion in the prior quarter.
- The five-year high for Non-Current Assets was $91.1 billion in Q1 2022, with the low at $76.9 billion in Q1 2025.
- The 5-year median for Non-Current Assets is $80.6 billion (2024), against an average of $82.5 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets slipped 14.12% in 2022, then advanced 3.33% in 2023.
- Takeda Pharmaceutical's Non-Current Assets stood at $77.2 billion in 2022, then gained by 3.33% to $79.8 billion in 2023, then grew by 1.83% to $81.3 billion in 2024, then declined by 1.7% to $79.9 billion in 2025, then declined by 1.71% to $78.5 billion in 2026.
- Business Quant data shows TAK's Non-Current Assets at $78.5 billion in Q2 2026, $79.2 billion in Q1 2026, and $79.9 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.51 Bn |
| Mar 31, 2026 | 79.20 Bn |
| Dec 31, 2025 | 79.87 Bn |
| Sep 30, 2025 | 78.38 Bn |
| Jun 30, 2025 | 79.42 Bn |
| Mar 31, 2025 | 76.87 Bn |
| Dec 31, 2024 | 81.25 Bn |
| Sep 30, 2024 | 77.22 Bn |
| Jun 30, 2024 | 84.28 Bn |
| Mar 31, 2024 | 84.69 Bn |
| Dec 31, 2023 | 79.79 Bn |
| Sep 30, 2023 | 85.93 Bn |
| Jun 30, 2023 | 89.90 Bn |
| Mar 31, 2023 | 87.39 Bn |
| Dec 31, 2022 | 77.22 Bn |
| Sep 30, 2022 | 85.75 Bn |
| Jun 30, 2022 | 89.05 Bn |
| Mar 31, 2022 | 91.08 Bn |
| Dec 31, 2021 | 89.91 Bn |
| Sep 30, 2021 | 91.78 Bn |